Juanjuan Huang

Changsha, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS.

The real-world safety profile of enfortumab vedotin with or without pembrolizumab: insights from a comparative analysis of FAERS.

Journal: Frontiers in immunology

Published: March 15, 2026

Beyond nigrostriatal dopamine transporter loss: whole-brain DAT depletion patterns discriminate PD phenotypes.

Beyond nigrostriatal dopamine transporter loss: whole-brain DAT depletion patterns discriminate PD phenotypes.

Journal: European journal of nuclear medicine and molecular imaging

Published: October 21, 2025

Chromatin accessibility and transcriptome in human neuronal model exposed to Parkinson's environmental toxins.

Chromatin accessibility and transcriptome in human neuronal model exposed to Parkinson's environmental toxins.

Journal: Scientific data

Published: July 28, 2025

Personalizing voriconazole dosing in Chinese hematological patients: CYP2C19 phenotype and albumin-bilirubin grade as key predictors of trough concentrations.

Personalizing voriconazole dosing in Chinese hematological patients: CYP2C19 phenotype and albumin-bilirubin grade as key predictors of trough concentrations.

Journal: Frontiers in pharmacology

Published: July 17, 2025

Efficacy and safety of vitamin E as adjunctive therapy for epilepsy: a systematic review and meta-analysis of randomized control trials.

Efficacy and safety of vitamin E as adjunctive therapy for epilepsy: a systematic review and meta-analysis of randomized control trials.

Journal: Frontiers in neurology

Published: May 13, 2025

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).

Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).

Journal: PloS one

Published: April 01, 2025

The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR.

The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR.

Journal: CNS neuroscience & therapeutics

Published: March 26, 2025

Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database.

Adverse drug events associated with insulin glargine: a real-world pharmacovigilance study based on the FAERS database.

Journal: Frontiers in pharmacology

Published: January 19, 2025

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis.

Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis.

Journal: Frontiers in immunology

Published: September 12, 2024

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database.

Risks of malignancies related to disease-modifying antirheumatic drugs in rheumatoid arthritis: a pharmacovigilance analysis using the FAERS database.

Journal: Frontiers in pharmacology

Published: August 08, 2024

Efficient analysis of drug interactions in liver injury: a retrospective study leveraging natural language processing and machine learning.

Efficient analysis of drug interactions in liver injury: a retrospective study leveraging natural language processing and machine learning.

Journal: BMC medical research methodology

Published: May 15, 2024

Clinical application of voriconazole in pediatric patients: a systematic review.

Clinical application of voriconazole in pediatric patients: a systematic review.

Journal: Italian journal of pediatrics

Published: February 22, 2024

Showing 1-12 of 22

Last Updated: 09/26/2026